A draft bill will be considered by the U.S. House of Representatives that would increase the power of the Food and Drug Administration (FDA) to monitor the side effects of drugs on the market. The bill would allow the FDA to impose fines on companies that fail to comply with its directions to study medications after approval.

For more information, please see: